Horizon Therapeutics (HZNP) Misses Q2 EPS by 26c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Horizon Therapeutics (HZNP) Misses Q2 EPS by 26c

Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance

August 3, 2022 7:00 AM EDT

Second-Quarter 2022 Results:
-- Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million --
-- GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million --
-- TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million --
-- KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Million --
-- Cash Position of $1.89 Billion as of June 30, 2022 --

Revises Full-Year 2022 Guidance:
-- Full-Year 2022 Net Sales Guidance of $3.53 Billion to $3.60 Billion, Reflecting Revised Net Sales Expectations for TEPEZZA and Inflammation Segment... More